Correction to: Oncogene https://doi.org/10.1038/s41388-021-02020-z, published online 23 September 2021
In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.
Rights and permissions
About this article
Cite this article
Moskovich, D., Finkelshtein, Y., Alfandari, A. et al. Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene 42, 1508 (2023). https://doi.org/10.1038/s41388-023-02629-2